NCT03599453View on ClinicalTrials.gov

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 9, 2019

Primary Completion Date

September 2, 2020

Study Completion Date

March 21, 2023

Conditions
Triple -Negative Breast CancerEstrogen Receptor NegativeHER2/Neu NegativeAnatomic Stage IV Breast Cancer AJCCProgesterone Receptor Negative
Interventions
PROCEDURE

Biopsy

Undergo Biopsy

PROCEDURE

Chemokine Modulation Therapy

Undergo chemokine modulation therapy

DRUG

Celecoxib

Given by mouth

BIOLOGICAL

Recombinant Interferon Alfa-2b

Given intravenously

DRUG

Rintatolimod

Given intravenously

BIOLOGICAL

Pembrolizumab

Given intravenously

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

AIM ImmunoTech Inc.
All Listed Sponsors
collaborator

AIM ImmunoTech Inc.

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER